MELBOURNE, Australia, Nov 25 (Bernama) -- Gordagen Pharmaceuticals, a privately held Australian company commercializing tocotrienol-based nutraceuticals and pharmaceuticals, today outlined the strategic initiatives it is taking in preparation for commercializing its first nutraceutical product in the US early next year.
As part of the Company's long-term growth strategy and shift toward commercial operations with the potential to have multiple marketed products in the coming years, Chairman of the Board, Mr Fred Nadjarian, has announced his retirement from the Board and will assume the role of Special Advisor to the Scientific Advisory Board.
http://mrem.bernama.com/viewsm.php?idm=25813
No comments:
Post a Comment